P3‐383: The MARQ‐AD: A new measure of interview quality in Alzheimer's disease trials | Zendy

Weber Christopher J. | Zendy; De Santi Susan | Zendy; Kirby Louis C. | Zendy; Williams Janet B.W. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

P3‐383: The MARQ‐AD: A new measure of interview quality in Alzheimer's disease trials

Author(s) -

Weber Christopher J.,

De Santi Susan,

Kirby Louis C.,

Williams Janet B.W.

Publication year - 2010

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2010.05.1925

Subject(s) - measure (data warehouse) , alzheimer's disease , psychology , disease , gerontology , medicine , clinical psychology , computer science , data mining

Clinician-administered cognitive assessments in Alzheimer's disease are used to detect treatment effects, but can also diminish or obscure a treatment effect when scale rating variability is introduced. The MedAvante Analysis of Rating Quality Alzheimer's Disease (MARQ-AD) was developed specifically for Alzheimer's rating scales to identify administration and scoring deviations in AD assessments in randomized clinical trials.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research